Table 5.
Marketed HME products of poorly soluble drugs summarized for indication, type of dosage form and polymer employed.
| Brand Name | API | Polymer | Indication | Dosage form | Manufacturer/Status | Ref |
|---|---|---|---|---|---|---|
| Gris-PEG | Griseofulvin | PEG | Onychomycosis | Oral Tablet (Crystalline dispersion) | Pedinol Pharmacal (Marketed) | (Ahmed et al., 2010) |
| Norvir® | Ritonavir | PEG-glyceride | Viral infection (HIV) | Oral Tablet (Amorphous dispersion) | AbbVie (Marketed) | (Sherman and Steinberg, 2011) |
| Kaletra® | Ritonavir, Lopinavir | PVP/PVA | Viral infection (HIV) | Oral Tablet (Amorphous dispersion) | AbbVie (Marketed) | (Klein et al., 2007) |
| Onmel® | Itraconazole | HPMC | Onychomycosis | Oral Tablet (Amorphous dispersion) | Merz North American, Inc. (Marketed) | (Baert et al., 2003) |
| Viekirapak | Ombitasvir, Paritaprevir, Ritonavir, Dasabuvir | PVP/VA copolymer | Anti-viral (HIV) | Oral Tablet (Amorphous dispersion) | AbbVie (Marketed) | (Miller et al., 2016) |
| Belsomra ® | Suvorexant | PVP/VA copolymer | Insomnia Treatment | Oral Tablet (Amorphous dispersion) | Merck (Marketed) | (Harmon and Variankav al, 2013) |
| Noxafil® | Posaconazole | HPMCAS | Anti-fungal | Oral Tablet (Amorphous dispersion) | Merck (Marketed) | (Haser et al., 2016) |
| Anacetrapib | Anacetrapib | PVP/VA copolymer | Cardiovascular disease | Oral Tablet (Amorphous dispersion) | Merck (Development) | (Haser et al., 2016) |
| Venclexta™ | Venetoclax | PVP/VA copolymer | Oncology | Oral Tablet (Amorphous dispersion) | AbbVie (Development) | (Haser et al., 2016) |
| Rezulin® | Troglitazone | PVP | Diabetes | Oral Tablet (Amorphous dispersion) | Wyeth (Withdrawn) | (Terife, 2013) |